# Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

Source: https://onco.cc/trials/nct04928222/  
OnCo record `nct04928222` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Doxorubicin in basal cell carcinoma, run by SkinJect, Inc., active and no longer recruiting.

## Summary

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) is a phase 1/2 interventional study registered as NCT04928222 by SkinJect, Inc., with 25 participants enrolled, started 2021-09-24 and due to reach its primary completion in 2023-12-30. Interventions recorded: Doxorubicin-containing MNA and Placebo-containing MNA.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04928222
- Phase: 1/2
- Setting: A Trial to Evaluate Placebo Microneedle Arrays in Healthy Human Volunteers (Part I), Followed by Proof of Concept Testing of Efficacy and Safety of Doxorubicin Microneedle Arrays in Subjects With Basal Cell Cancer (Part II)
- Sponsor: SkinJect, Inc.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT04928222: https://clinicaltrials.gov/study/NCT04928222

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/)

---
JSON: https://onco.cc/api/v1/entities/nct04928222.json